thanks don. i just looked at a chart, after november it has traded between 6 and 9. 6.5 to 6.6 held 3 times. failed 9 breaking through 9 twice. it broke through 7 (to the upside) 3 times. longer term support was 3.60 (november) and resistance 13.20 (may). amazing to me that the "eve of commercialization" has passed, and now we're in the "dawn of sales" and dimthaid is oversold.
i've bet my future on dimethaid, but now i'm up to 700 shares of provalis. my point is that provalis and dimethaid split england pennsaid revenue, with provalis getting the larger shares. also ,
> "have some activities in the pharma development area. That area, I have no idea about. "
yes, they are very successful in selling a blood sugar test, and those sales are expanding rapidly. analysts are saying that the price of provalis is justfied by that alone, without pennsaid. from what i can tell, provalis has done an extremely good job of restructuring itself and is losing much less that it was. so i figured if they get this huge pennsaid cash flow, kaboom. i have no clue on the expense side of things though who is going to have to spend much more money faster. but i saw that 3 provalis
execs bought over 70k shares this week.
jeffS |
